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A B S T R A C T
The aim of this study was to investigate the diffusion lung capacity in patients with untreated hypertension. For this
purpose, a total of 30 cases and 30 controls were included in the present study, which was based on several spirometry in-
dicators in the analysis. The measurements were based on »single breath approach«. The results indicated that the two
groups differed in several spirometry results, including vital capacity, maximum willing ventilation, but the overall lung
diffusion capacity did not seem to be significantly different between cases and controls. The results suggest that although
there is a strong link between respiratory and circulatory system, the overall lung diffusion capacity is not altered by the
increased arterial pressure and hypertension. Furthermore, the results of this suggest the need for creation of the popula-
tion-specific spirometry standards for the population of Herzegovina in order to provide more meaningful results of
spirometry.
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Introduction
Arterial hypertension is defined as the increased level
of systolic and/or diastolic blood pressure. The main con-
sequence of this situation is increased minute volume or
peripheral resistance, both leading to increased work-
load1. However, the physiological mechanism associated
with these changes is by far more complicated and it is
governed by a multitude of other factors, including car-
diac work, vascular system characteristics, total blood
volume and blood viscosity2. This system is governed by
four basic mechanisms – nervous, voluminous, humoral
and adrenal, all being involved in the complex pathways,
what is important for understanding of the disorders in
the blood pressure determination3,4.
Epidemiological and intervention studies suggest that
there is no natural cut-off point at which hypertension
can be diagnosed5,6, and that each cut-off point should be
individually defined5. Currently, formal hypertension cut-
-off point is considered as the systolic blood pressure of
up to 17.2 kP (120 mmHg), while diastolic cut-off is 11.3
kP (85 mmHg), leading to the conclusion that hyperten-
sion is diagnosed when either of these two pressures
crosses the cut-off point5,6.
However, the measurement of the blood pressure
should reside in a highly control measurement protocol,
with diagnosis of hypertension being made only if three
consecutive increased values of blood pressure are re-
corded in at least two separate measurements7. After
this, a careful physical examination should establish the
predominant patter of the blood pressure changes, diag-
nosis essential or secondary hypertension, whether there
are other organs affected, or are there other risk factors
that may aggravate hypertension6. Suggested laboratory
tests include glucose, total cholesterol, HDL, triglycer-
ides, uric acid, creatinine, sodium, potassium, hemoglo-
bin, haematocrit, urine dip-test and ECG (occasionally
postprandial glucose or oral glucose tolerance test should
be performed if the initial glucose values are elevated)8,9.
In addition, it should also be noted that various phenom-
ena within lungs can also affect blood pressure, in sev-
eral ways.
The aim of this study was to measure the total diffu-
sion capacity of the lungs in patients with arterial hyper-
tension.
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Patients and Methods
A total of 30 patients with untreated arterial hyper-
tension were included in the current study. All patients
were men, aged 30–55 years. Exclusion criteria were sec-
ondary hypertension, pulmonary diseases, cardiac de-
fects, arrhythmia, conduction problems, ischemic heart
disease and those whose functional capacity was NYHA
III-IV. Additionally, smokers were also excluded. The con-
trol group consisted of the same number of respondents
without indication of arterial hypertension. The study
was performed during May 2007-March 2009, at the
Sports Medicine Center Diomed in Split, Croatia.
All patients underwent spirometry measurement, ac-
cording to the American Thoracic Society protocol10. The
measurement included vital capacity (VC), forced vital
capacity (FVC), forces expiratory volume in one second
(FEV1), Tiffeneaun index (the ratio of FEV1/FVC), maxi-
mum willing ventilation (MWV), maximum expiratory
flow at 50% FVC (MEF50) and forced expiratory flow at
25% FVC (MEF25), presenting the flow-volume curve11.
The diffusion lung capacity was measured using »sin-
gle breath« approach, with carbon monoxide emission
using Cosmed 4. The patient initially exhales to reach
the residual volume, and then quickly inhales the test
mixture (0.2–0.3% CO, 10–14% He, 18–21% O2, the rest
N2). After the inhalation, at least 90% of the vital capac-
ity should be retained and the respiratory muscles re-
laxed. This inhibits negative thoracic pressure which
could affect the results. Ten seconds after apnea patients
are asked to exhale quickly. The first 600–800 ml is col-
lected into a bag for the analysis. The analysis includes
CO and He concentration, and is repeated five minutes
after the initial procedures12. The results depend on sev-
eral parameters, such as age, height and gender13.
Statistical analysis included t-test for two numerical
groups with normal data distribution. The significance
was set at p<0.05.
Results
A total of 30 cases and 30 controls were included in
the present study. The initial analysis suggested some
differences in terms of the basic characteristics (Table 1).
Similarly, significant differences were seen in some lung
indicators. The average VC of cases was 80.66±5.82,
while in controls the average values for the same parame-
ter was 97.00±8.17 (t=8.91; p<0.001). The average FEV1
in cases was 70.53±4.99 %, while in controls it was
86.83±7.17 % (t=10.21; p<0.001). Similar differences
were recorded for other indicators (Table 2).
Discussion
The results of this study show that some lung param-
eters change in patients with hypertension. This is pri-
marily related to various functional lung capacity indica-
tors. The lung diffusion capacity may be used as one of
the basic diagnostic tools in the cardio-respiratory sys-
tem evaluation. Although some of these indicators may
have limited meaning, they nevertheless provide unique
insight into the mechanisms leading to the affected lung
function14.
The efficacy of the gas exchange in the lungs depends
on a number of potential factors, such as thickness and
the total surface of the alveolar membrane, volume of the
blood in these capillaries, hemoglobin concentration and
the affinity towards carbon monoxide and the ventila-
tion-perfusion ratio, it becomes obvious that there is a
myriad of possible conditions which may affect it15,16.
In terms of this study, it should be noted that the
cases and controls differed in the weight and body mass
index, but neither of these two characteristics is likely to
affect the functional diagnostics of the lung as well as the
diffusion capacity10. Additionally, the Cotes correction
was planned (which is usually used to adjusts the find-
ings in cases of polycytemia, and hemoglobin)17. How-
ever, neither of the patients was required to undergo this
correction. Also, we did not need to adjust for the carbo-
xyhemoglobin concentration, as neither of the patients
required such a correction.
It might seem that the spirometry has limited value
in hypertension diagnostics. However, it is a diagnostic
tool for the lung capacity, which is linked to the arterial
hypertension. Yet, the main value of spirometry is associ-
ated with lung function, and the results should be ad-
justed for age, height and gender13.
The results of spirometry were within suggested ran-
ges in most patients. However, we did record a significant
difference in VC between cases and controls, as well as
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TABLE 2
SPIROMETRY RESULTS, DIFFUSION CAPACITY AND OTHER
LUNG INDICATORS OF THE CASES AND CONTROLS
Variable
Mean and standard deviation
t p
Cases Controls
VC 80.6±5.8 97.0±8.1 8.91 <0.001
FEV1 70.5±4.9 86.8±7.1 10.21 <0.001
MWV 79.6±8.8 98.8±11.2 7.35 <0.001
DLCO 93.5±8.4 93.6±6.4 0.05 0.959
KCO 77.5±7.4 88.7±5.2 6.75 <0.001
TABLE 1
CLINICAL CHARACTERISTICS OF THE INCLUDED PATIENTS
AND CONTROLS
Variable
Mean and standard deviation
t p
Cases Controls
Age 54.0±7.2 59.0±19.4 1.30 <0.201
Height 178.46±5.11 182.36±7.28 2.40 0.020
Weight 96.6±19.8 83.9±11.9 3.00 <0.004
Body mass
index
31.5±4.0 26.4±2.8 5.72 <0.001
the FEV1 and MWV. This could be associated with the
wide tolerance of the normal spirometry range. While the
lower limit is 80% of the standard values, this might not
be treated as the referent range for any population, and
in this case it might suggest that it does not provide a
good reference range for the population of Herzegovina
which is likely to have greater average values for most
parameters. Additionally, the range also seems to wide,
40% of standard value. The main conclusion of this line
of research is that the population in Herzegovina is dif-
ferent from the expected norm and that the future stud-
ies should focus on creation of the population-specific
spirometry standards.
The results show that the diffusion capacity in both
cases and controls was close to 94% of standard values,
suggesting that there was no significant difference be-
tween these groups. This suggests that the diffusion ca-
pacity of the lung remains stable even in the cases of un-
treated hypertension18.
The shortcomings of this study include the low num-
ber of patients and controls, the possibility that other
mechanisms may be in place and the possibility that
there are different clinical and histological types of dis-
eases under study, which might have different implica-
tions on results due to possible various mechanisms that
lead to the diseases development. However, this study
presents almost a pioneering attempt to understand the
link between the lung diffusion capacity and arterial hy-
pertension. The main conclusion is the need to create the
population-specific spirometry range curves, aiming to
provide more precise and more informative estimates for
the lung indicators in the population of Herzegovina.
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DIFUZIJSKI KAPACITET PLU]A KOD PACIJENATA S HIPERTENZIJOM
S A @ E T A K
Cilj ovog rada bio je istra`iti povezanost izme|u difuzijskog kapaciteta plu}a i arterijske hipertenzije. U tu svrhu
prikupljeni su podaci 30 pacijenata sa nelije~enom hipertenzijom i 30 kontrola, kojima je ura|ena spirometrija kao
glavni pokazatelj funkcionalne sposobnosti plu}a. Mjerenja su se zasnivala na metodi jednog udaha. Rezultati pokazuju
da su postojale statisti~ki zna~ajne razlike u nekim rezultatima spirometrije, uklju~uju}i vitalni kapacitet, najve}u volj-
nu ventilaciju, ali da ukupan difuzijski potencijal plu}a nije bio umanjen kod pacijenata s nelije~enom hipertenzijom.
Unato~ sna`noj povezanosti plu}nog i krvo`ilnog sustava, difuzijski kapacitet nije umanjen kod pacijenata sa hiper-
tenzijom. Dodatan rezultat ovog rada je ukazivanje na potrebu izrade spirometrijskih normi za populaciju Hercegovine.
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